New Lifetime High Reached By MedAssets (MDAS)

Trade-Ideas LLC identified MedAssets ( MDAS) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified MedAssets as such a stock due to the following factors:

  • MDAS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $50.1 million.
  • MDAS has traded 502,306 shares today.
  • MDAS is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDAS with the Ticky from Trade-Ideas. See the FREE profile for MDAS NOW at Trade-Ideas

More details on MDAS:

MedAssets, Inc., a performance improvement company, provides technology-enabled products and services for hospitals, health systems, non-acute healthcare providers, payers, and other service providers and product manufacturers in the United States. Currently there are no analysts that rate MedAssets a buy, 1 analyst rates it a sell, and 15 rate it a hold.

The average volume for MedAssets has been 1.1 million shares per day over the past 30 days. MedAssets has a market cap of $1.9 billion and is part of the technology sector and computer software & services industry. The stock has a beta of 1.05 and a short float of 2.1% with 0.70 days to cover. Shares are up 1.2% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates MedAssets as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

Highlights from the ratings report include:
  • Compared to its closing price of one year ago, MDAS's share price has jumped by 67.99%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
  • MDAS's revenue growth trails the industry average of 28.5%. Since the same quarter one year prior, revenues slightly increased by 8.1%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • The gross profit margin for MEDASSETS INC is currently very high, coming in at 75.26%. Regardless of MDAS's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, MDAS's net profit margin of -1.17% significantly underperformed when compared to the industry average.
  • Currently the debt-to-equity ratio of 1.80 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. Along with this, the company manages to maintain a quick ratio of 0.44, which clearly demonstrates the inability to cover short-term cash needs.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Technology industry and the overall market, MEDASSETS INC's return on equity significantly trails that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Join Jim Cramer's Club During Our '12 Days of Holiday Deals' Sale and Save 66%!

Join Jim Cramer's Club During Our '12 Days of Holiday Deals' Sale and Save 66%!

Your Worst Enemy In a Bear Market Is Yourself

Your Worst Enemy In a Bear Market Is Yourself

Economist Perspective: Brexit Endgame in Sight?

Economist Perspective: Brexit Endgame in Sight?

Flashback Friday: Johnson & Johnson Hits Take Historic Plunge

Flashback Friday: Johnson & Johnson Hits Take Historic Plunge